CD79A and Recurrent upper respiratory tract infections: Additionally, SARS-CoV-2 can establish upper respiratory tract infections, resulting in the production of IgA antibodies, which have been shown to play a dominant role in early protection from infection [12,42]; therefore, we measured the levels of anti-N and anti-RBD IgA antibodies as well.